DINESH

Yatharth Hospital

Industry: Healthcare
Latest CMP 845
Today's Change ▲ 0.01%
52-Week High / Low 898 | 550
Price Date: 14-Aug-2026
Recommendation Hold
Target Price 1,024
Expected Upside 10.1%
Forecast Horizon 2 Years
Historical CAGR Not Available
1,000 Invested
Today's Value
Investment Period < 5 Years

Stock Snapshot

Post Results Return
+2.4%
Neutral Market Reaction
1-Year Target Price
858
2-Year Target Price
1,024
52-Week High / Low
898 / 550
20-Day Return
-0.4%
Market Cap (Cr.)
8,139
Current PE
46.4
P/BV Ratio
4.6
Dividend Yield
Industry PE
57.2

Price Performance

Basis of our Recommendation

Yatharth Hospital's management has articulated a clear growth strategy focused on expanding its operational bed capacity to 5,000 by FY29, leveraging a cluster-based approach in high-potential regions. This strategy is expected to enhance revenue through increased average revenue per occupied bed (ARPOB) as new facilities mature and integrate high-end tertiary care services. Despite facing execution risks associated with rapid expansion, management's confidence in operational efficiency and strong internal accruals supports Vista's forecast of moderated revenue growth and stable margins. The healthcare sector's current dynamics, characterized by stable pricing power but emerging margin pressures, align with Vista's outlook of a fair valuation and a cautious investment recommendation. Over the next 12-24 months, key opportunities include the successful integration of new assets and the potential for ARPOB growth, while watchpoints include execution risks and competitive pressures that could impact margins. Overall, Yatharth Hospital is positioned to capitalize on the growing demand for organized healthcare, although vigilance is required regarding operational execution and market dynamics

👍 Why We Like This Stock

  • Management's aggressive expansion strategy aims to increase operational bed capacity to 5,000, enhancing revenue potential
  • Focus on high-end tertiary care services is expected to drive ARPOB growth, supporting revenue stability
  • Strong internal accruals and operational efficiency provide a buffer against execution risks

Things To Watch Out For

  • Execution risks related to rapid capacity expansion could impact operational performance
  • Emerging margin pressures in the healthcare sector may challenge profitability
  • Competitive dynamics in the fragmented healthcare market could affect market share and pricing power

Key Parameters

Balance Sheet Strength
Conservatively Financed
Market Share
Stable
Industry Outlook
Stable
Analyst View
Strong Buy
Dividend History
Irregular
FII Holdings
Stable

Financial Snapshot

Actuals Forecast
FY24 FY25 FY26 FY27 FY28
Revenue (Cr.) 635 860 1,207 1,376 1,735
Profit Before Tax (Cr.) 157 170 224 210 283
PBT Margin 24.7% 19.8% 1855.8% 15.2% 16.3%
Net Profit (Cr.) 116 122 170 159 208
Earnings Per Share 12.0 12.7 18.2 16.0 21.6

Analyst Recommendations

Broker Recommendation Target Price Date
Choice Equity ▲ Buy 1,100 12-Aug-2026
Nuvama ▲ Buy 950 27-May-2026
Consensus Recommendation ▲ Strong Buy
Consensus Target 1,025
Coverage 2 Analysts
Analysts' Viewpoint
Yatharth Hospital's strategy to expand its bed capacity to 5,000 through acquisitions and brownfield projects in North India underpins analysts' positive outlook. The focus on high-margin specialties like oncology and organ transplants is expected to enhance ARPOB and revenue quality. While execution risks and regional concentration present challenges, the company's strong operational ramp-up and clear capital allocation plan support confidence in sustained revenue and margin growth over the next few years.

Company Overview

Show Company Profile

Yatharth Hospital & Trauma Care Services Limited, together with its subsidiaries, owns and operates super-specialty hospitals in India. The company offers services in the areas of medicine, cardiology, neurosciences, general surgery, nephrology and urology, pediatrics, gastroenterology, pulmonology, gynecology, orthopedics, spine and rheumatology, plastic and cosmetic surgery, ear, nose, throat, endocrinology, critical care, dermatology, nuclear medicine, and cancer and bone marrow transplant. It also provides services in the areas of GI surgery and liver transplant, robotic surgery, kidney transplant, IVF and fertility, emergency medicine, ophthalmology, dentistry, psychology and psychiatry, physiotherapy and rehabilitation, anesthesiology, radiology, pathology and laboratory medicine, nutrition and health, interventional spine and pain medicine, neurology, neurosurgery, and cardiovascular and thoracic surgery. In addition, the company sells medicines and canteen food. The company was incorporated in 2008 and is based in Noida, India.